AI in Clinical Trials: Where It Helps Sponsors, CROs and Sites, and the Regulatory Frame in 2026

Where AI fits across a clinical trial

A clinical trial generates documents at every stage, written by different organisations under strict version control. That makes trials a natural target for language models and also a demanding one, because nearly every document either contains patient data or becomes part of a regulatory record.

The table maps common tasks to the party that usually owns them.

The rest of this guide takes the stages in order, then turns to the rules. Regulatory sources were read on FDA, EMA, ICH and Federal Register pages on 25 October 2026.

AI for clinical trial design: protocols and feasibility

Protocol drafting and review

Protocols are long, and inconsistencies between their sections are easy to miss: a visit window in the schedule of assessments that differs from the text, an endpoint described one way in the synopsis and another in the statistical section, an exclusion criterion that contradicts a permitted medication list. A model working from the sponsor’s protocol template can draft routine sections and, more usefully, compare sections against each other and list every mismatch with page references.

It can also check a draft against internal standards, such as required safety language or the sponsor’s library of standard eligibility criteria. The scientific choices, including endpoints, comparators, sample size and the estimand, belong to the clinical and statistical team.

Eligibility criteria and feasibility

Restrictive eligibility criteria can slow enrolment. Before a protocol is final, teams can run each criterion against de-identified or aggregated real-world data to see how many patients would remain after each filter. A language model helps by translating free-text criteria into structured queries and explaining which criterion removes the most patients.

Site selection

Feasibility questionnaires, past enrolment performance, investigator CVs and site capability documents are text that models can summarise into a comparable profile for each site. The output is a shortlist for the clinical operations lead, not a decision. Where the data comes from a CRO’s proprietary site database, the contract usually limits how it can be processed.

AI for clinical trial recruitment and patient matching

Of all the tasks in this guide, recruitment works with the most sensitive data. The typical design runs at the site or the health system, because that is where the patient records live.

A matching workflow usually has four steps:

1. Criteria parsing. The protocol’s inclusion and exclusion criteria are broken into individual checks.
2. Record review. For each patient, the model reads structured data such as diagnoses, labs and medications, and free text such as clinic notes and pathology reports.
3. Evidence per criterion. The output marks each criterion as met, not met or unknown, quoting the passage behind each judgement.
4. Coordinator review. A research coordinator or investigator confirms eligibility before anyone contacts the patient.

Oncology shows why step three matters. Criteria such as biomarker status, number of prior lines of therapy and time since last treatment are often buried in narrative reports. A list of candidates without the supporting evidence forces the coordinator to redo the work; a list with quoted evidence lets them verify in minutes.

The privacy basis comes first. In the US, a covered entity can let a researcher review PHI to prepare a protocol or identify candidates under the HIPAA provision for reviews preparatory to research, which requires the researcher to state that the review is solely for that purpose, that no PHI will leave the covered entity and that the PHI is necessary. An IRB or privacy board waiver of authorization is the other common route. In the EU, health data is a special category under GDPR and needs both a lawful basis and an Article 9 condition. Running the matching model inside the hospital network fits the requirement that PHI not leave the covered entity during a preparatory review. The healthcare and life sciences solution describes that site-side deployment.

Informed consent and plain-language documents

Consent forms are legal documents that must also be readable. FDA’s informed consent regulation at 21 CFR 50.20 requires that the information given to a subject be in language the subject can understand. In the EU, the Clinical Trials Regulation (EU) No 536/2014 asks sponsors to submit a summary of results together with a summary a layperson can understand.

Models are good at rewriting dense text at a lower reading level, and at checking that a consent form covers every required element. Three cautions apply:

• Meaning must not drift. A simplified sentence about risks or alternatives can lose a qualifier that matters. Each change should be reviewed against the source text by someone who understands the protocol.
• Translations need the same review. Machine translation of consent forms still goes through the sponsor’s certified translation and back-translation process where that is required.
• The IRB or ethics committee approves the final text. AI shortens the drafting cycle; it does not change who approves the document.

E6(R3) also recognises electronic consent, noting that when computerised systems are used to obtain consent, trial participants may lack familiarity with them. Plain-language drafting supports that concern.

AI for clinical trial management: monitoring, deviations and the TMF

Monitoring and deviation review

ICH E6(R3) puts quality by design and risk-based quality management at the centre of trial oversight. Monitors produce visit reports, sites log protocol deviations, and central monitoring teams look for patterns. A model can summarise a month of monitoring reports by site, group deviations by type and highlight sites where the same issue keeps recurring. That shortens the path from data to a corrective action, while the decision about what counts as an important deviation stays with the study team.

Trial master file quality control

TMF quality checks are repetitive and well defined: is the document the right type, is it filed in the right place, is it signed and dated, does the version match the approved version, is the site and study identifier correct. A model can classify incoming documents, extract signatures and dates, and flag likely misfilings for a TMF specialist to resolve. This is an inspection-readiness task, so the checks and their results should be logged.

Computerised systems and Part 11

E6(R3) states that computerised systems used in trials should be fit for purpose, for example through risk-based validation where appropriate. In the US, 21 CFR 11.10 requires controls for closed systems that create or maintain electronic records, including validation and secure, computer-generated, time-stamped audit trails. When AI output becomes part of a regulated record, such as a filed document or a data change, the system producing it needs the same audit trail and access controls as any other trial system. Our guide to GxP validation for AI and LLMs sets out how to scale validation to risk.

Safety narratives and clinical study reports

Safety narratives. Narratives for serious adverse events and other events of interest follow a predictable structure: patient demographics, medical history, study drug exposure, event onset and course, treatment, outcome and causality assessment. Most of the facts are in the safety database, the case report forms and source documents. A model can draft each narrative from those inputs with references back to the data, leaving the safety physician to review the clinical reasoning. The same intake and extraction skills apply after approval, as the pharmacovigilance case intake use case shows.

Clinical study reports. A CSR follows the ICH E3 structure and draws on the protocol, the SAP, tables, listings and figures, and the narratives. Models can draft methods sections from the protocol, describe results from finished tables, and check that numbers in the text match the tables. Medical writers keep responsibility for interpretation and for the story the report tells. The pharma regulatory submissions playbook describes how such drafting runs with source citations and reviewer sign-off.

Literature support. Background sections, comparator context and safety signal reviews depend on the published literature. Retrieval over a curated library with citations, as in the research and literature review use case, keeps those sections traceable.

AI in clinical trials: the FDA, EMA and ICH frame in 2026

ICH E6(R3). ICH adopted the revised principles and Annex 1 of its good clinical practice guideline on 6 January 2025. In the EU they came into effect on 23 July 2025. FDA published E6(R3) as final guidance in September 2025, with the Federal Register notice on 9 September. Annex 2, which covers pragmatic and decentralised trials and trials that use real-world data sources, reached ICH Step 4 on 3 June 2026 and comes into effect in the EU on 15 January 2027. FDA issued Annex 2 as draft guidance in December 2024 and had not published a final version in the Federal Register by 25 October 2026.

FDA’s draft guidance on AI for regulatory decision-making. In January 2025 FDA released the draft guidance Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products. It proposes a risk-based credibility assessment for AI models used to produce information about safety, effectiveness or quality, organised around the model’s context of use. It remained a draft on 25 October 2026. The scope matters for most of the tasks above: the draft does not address AI used for operational efficiencies, such as internal workflows, resource allocation or drafting a regulatory submission, where that use has no impact on patient safety, drug quality or how reliable the study results are.

Joint FDA and EMA principles. In January 2026 EMA and FDA issued a joint set of ten principles for good AI practice in drug development. They include a risk-based approach, adherence to GxP standards, a clear context of use, documented data governance and life cycle management with monitoring for issues such as data drift.

EMA’s reflection paper. EMA’s reflection paper on AI across the lifecycle of medicines appeared on 30 September 2024. It covers AI use from development through authorisation and post-authorisation.

FDA’s early-phase pilot. In April 2026 FDA requested information on a proposed pilot to assess how AI can improve decision-making in early-phase trials, including safety monitoring and dose selection, guided by principles aligned with the NIST AI Risk Management Framework. Comments closed on 29 June 2026.

For most sponsors the practical reading is simple. AI that drafts and checks documents under human review sits in the operational space and is governed by the quality system and Part 11. AI whose output feeds a regulatory decision about safety or efficacy needs a defined context of use, credibility evidence and early conversation with the regulator.

Patient data, HIPAA, GDPR and where the models run

Trial data moves between sites, CROs, central labs, vendors and the sponsor, usually pseudonymised once it leaves the site. Each hop has its own agreement. Sending that data to a third-party AI service adds a processor to the chain, which in the EU means a data processing agreement and, for transfers outside the EEA, a transfer mechanism. Site-side tasks that touch identifiable records, such as patient matching, fall under HIPAA in the US.

Sponsors also hold confidential material that never contained patient data but is still sensitive: unpublished efficacy results, protocol designs competitors would value, and regulatory correspondence. Many sponsors and CROs therefore run models for trial documents on infrastructure they control, with cloud models limited to public or low-sensitivity work. The broader case for that approach in drug development is covered in our guide to private AI across pharmaceutical and life sciences companies.

How VDF AI fits a sponsor, CRO or site

VDF AI is an AI platform that sponsors, CROs and research sites install on their own servers, in a private cloud or on an isolated network. Configured for local models only, it keeps protocols, eligibility screening inputs, retrieved document passages, indexes, history and logs within the organisation; no prompt or passage goes to a third-party model service. VDF AI has no regulatory approval or qualification of its own and does not replace a sponsor’s validation; it runs inside the customer’s quality system and computerised system validation process.

For trial work, each study can have its own knowledge collection with access limited to the study team, and permission-aware retrieval only returns passages from documents a user may open. Governed agents can run the repeatable steps described here, such as protocol consistency checks, TMF classification, deviation summaries and narrative drafts, with tool permissions set per role and an approval step before output becomes a controlled document. Each run keeps an audit trail of the requester, the model, the passages used and the tools called, which supports the traceability E6(R3) and Part 11 expect. At a site, the same platform can screen records against eligibility criteria inside the hospital network, with the coordinator confirming every candidate.

In the VDF AI Router, the team lists the open-weight models it runs on Ollama, vLLM or other OpenAI-compatible servers, sets routing rules and budgets, and logs every call; a cloud model is added only where policy allows, for instance to summarise published papers. For sign-in, Microsoft Entra ID works out of the box on-premises, while organisations on Okta, Keycloak or another SAML or OIDC identity provider route through an SSO-aware reverse proxy, and every plan includes role-based access control. Organisations that want to test a single study workflow first can start with a three-month on-premises platform trial.

The healthcare AI use case library lists related workflows. Before choosing a first study, the free AI readiness assessment shows whether data access, validation capacity or skills will set the pace. This guide is general information, not regulatory advice for a specific trial.